Free Trial Information
BioCentury | Jan 23, 2021
Management Tracks

Yale’s Fuchs joins Genentech, Roche; plus Lineage’s Roberts jumps on Longboard as CFO and Avidity, Xalud, AVM, Novavax

...is director of the Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital.Brandi Roberts left Lineage Cell Therapeutics Inc....
Read More
BioCentury | Dec 2, 2020
Emerging Company Profile

Sofinnova’s Papiernik, Costa and Roche alum Garibaldi carve orphan neurology play Noema out of the pharma’s assets

...Novuspharma S.p.A., which was acquired by CTI BioPharma Corp. (NASDAQ:CTIC...
Read More
BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

...By BioCentury Staff BrainStorm sees path forward for ALS therapy despite Phase III missBrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI...
...JITC).TARGETSGLP-1 – Glucagon-like peptide-1PSA (KLK3) - Prostate-specific antigenRHOC - Ras homolog family member C BC Staff BrainStorm Cell Therapeutics Inc. Novo...
Read More
BioCentury | Sep 3, 2020
Management Tracks

Dier joining Ultragenyx as CFO; plus Magenta, Galectin, Immunicum, BrainStorm, Vaccinex

...core duties as the immuno-oncology company’s CSO. Rohmann was acting CEO of Oasmia Pharmaceutical AB (SSE:OASM).BrainStorm Cell Therapeutics Inc....
Read More
BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

...Investment Authority, the sovereign wealth fund for the State of Qatar. Neurodegenerative diseases company BrainStorm Cell Therapeutics Inc....
...Sawka, Staff Writer Assembly Biosciences Inc. NGM Biopharmaceuticals Inc. TCR2 Therapeutics Inc. Amunix Pharmaceuticals Inc. Evox Therapeutics Ltd. Vor Biopharma Inc. BrainStorm Cell Therapeutics Inc. Sierra...
Read More
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

..."ORIC Raises $55M to Fund Trials in Drug Resistant Cancers" ). Neurodegenerative diseases company BrainStorm Cell Therapeutics Inc....
...of rare disease development at Orion Corp. (HSE:ORNAV; HSE:ORNBV). Robin Sawka, BioCentury Staff Locana Inc. Assembly Biosciences Inc. BrainStorm Cell Therapeutics Inc. Promethera...
Read More
BioCentury | Jul 29, 2019
Company News

July 29 Management tracks: Verastem names CEO; plus Zealand, Turning Point, Arvinas and more

...CFO, who is leaving to pursue other opportunities. Rubin was EVP and CFO at BrainStorm Cell Therapeutics Inc....
Read More
BioCentury | Apr 6, 2019
Finance

Everybody up

...by 3 months to September the review of a BLA for MVA-BN smallpox vaccine CTI BioPharma Corp. (NASDAQ:CTIC...
Read More
BioCentury | Feb 8, 2019
Clinical News

CTI withdraws MAA for myleofibrosis therapy

...CTI BioPharma Corp. (NASDAQ:CTIC) withdrew its MAA for pacritinib to treat myelofibrosis following interactions with EMA's...
...design with FDA. FLT3 (CD135) - FMS-like tyrosine kinase 3; JAK-2 - Janus kinase-2 CTI BioPharma Corp. (NASDAQ:CTIC...
...Product: Pacritinib (BAX 2201, ONX 0803, SB1518) Business: Hematology Sandi Wong pacritinib (BAX 2201, ONX 0803, SB1518, enpaxiq) CTI BioPharma Corp. FMS-like...
Read More
BioCentury | Feb 1, 2019
Company News

CHMP recommendations include Ajovy, Vizimpro, Humira biosimilars

...IMC-3G3 (Compound #), olaratumab (Generic), Lartruvo (Other) pacritinib (BAX 2201, ONX 0803, SB1518, enpaxiq) Tecentriq/Avastin, atezolizumab/bevacizumab Vizimpro, dacomitinib (PF-00299804) CTI BioPharma Corp. Eli...
Read More
Items per page:
1 - 10 of 819
BioCentury | Jan 23, 2021
Management Tracks

Yale’s Fuchs joins Genentech, Roche; plus Lineage’s Roberts jumps on Longboard as CFO and Avidity, Xalud, AVM, Novavax

...is director of the Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital.Brandi Roberts left Lineage Cell Therapeutics Inc....
Read More
BioCentury | Dec 2, 2020
Emerging Company Profile

Sofinnova’s Papiernik, Costa and Roche alum Garibaldi carve orphan neurology play Noema out of the pharma’s assets

...Novuspharma S.p.A., which was acquired by CTI BioPharma Corp. (NASDAQ:CTIC...
Read More
BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

...By BioCentury Staff BrainStorm sees path forward for ALS therapy despite Phase III missBrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI...
...JITC).TARGETSGLP-1 – Glucagon-like peptide-1PSA (KLK3) - Prostate-specific antigenRHOC - Ras homolog family member C BC Staff BrainStorm Cell Therapeutics Inc. Novo...
Read More
BioCentury | Sep 3, 2020
Management Tracks

Dier joining Ultragenyx as CFO; plus Magenta, Galectin, Immunicum, BrainStorm, Vaccinex

...core duties as the immuno-oncology company’s CSO. Rohmann was acting CEO of Oasmia Pharmaceutical AB (SSE:OASM).BrainStorm Cell Therapeutics Inc....
Read More
BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

...Investment Authority, the sovereign wealth fund for the State of Qatar. Neurodegenerative diseases company BrainStorm Cell Therapeutics Inc....
...Sawka, Staff Writer Assembly Biosciences Inc. NGM Biopharmaceuticals Inc. TCR2 Therapeutics Inc. Amunix Pharmaceuticals Inc. Evox Therapeutics Ltd. Vor Biopharma Inc. BrainStorm Cell Therapeutics Inc. Sierra...
Read More
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

..."ORIC Raises $55M to Fund Trials in Drug Resistant Cancers" ). Neurodegenerative diseases company BrainStorm Cell Therapeutics Inc....
...of rare disease development at Orion Corp. (HSE:ORNAV; HSE:ORNBV). Robin Sawka, BioCentury Staff Locana Inc. Assembly Biosciences Inc. BrainStorm Cell Therapeutics Inc. Promethera...
Read More
BioCentury | Jul 29, 2019
Company News

July 29 Management tracks: Verastem names CEO; plus Zealand, Turning Point, Arvinas and more

...CFO, who is leaving to pursue other opportunities. Rubin was EVP and CFO at BrainStorm Cell Therapeutics Inc....
Read More
BioCentury | Apr 6, 2019
Finance

Everybody up

...by 3 months to September the review of a BLA for MVA-BN smallpox vaccine CTI BioPharma Corp. (NASDAQ:CTIC...
Read More
BioCentury | Feb 8, 2019
Clinical News

CTI withdraws MAA for myleofibrosis therapy

...CTI BioPharma Corp. (NASDAQ:CTIC) withdrew its MAA for pacritinib to treat myelofibrosis following interactions with EMA's...
...design with FDA. FLT3 (CD135) - FMS-like tyrosine kinase 3; JAK-2 - Janus kinase-2 CTI BioPharma Corp. (NASDAQ:CTIC...
...Product: Pacritinib (BAX 2201, ONX 0803, SB1518) Business: Hematology Sandi Wong pacritinib (BAX 2201, ONX 0803, SB1518, enpaxiq) CTI BioPharma Corp. FMS-like...
Read More
BioCentury | Feb 1, 2019
Company News

CHMP recommendations include Ajovy, Vizimpro, Humira biosimilars

...IMC-3G3 (Compound #), olaratumab (Generic), Lartruvo (Other) pacritinib (BAX 2201, ONX 0803, SB1518, enpaxiq) Tecentriq/Avastin, atezolizumab/bevacizumab Vizimpro, dacomitinib (PF-00299804) CTI BioPharma Corp. Eli...
Read More
Items per page:
1 - 10 of 819